Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [1][3]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to contact them regarding their legal rights [1]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives overstated the prospects of the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [3]. - The lawsuit claims that the misleading statements about Replimune's business and operations led to investor damages when the true details were revealed [3]. Group 3: Market Reaction - Following the announcement of a Complete Response Letter from the FDA regarding the Biologics License Application for RP1, Replimune's stock fell over 73% during intraday trading on July 22, 2025 [4].

Core Viewpoint - The FDA has canceled the advisory committee meeting for Biohaven's core drug, trorluzole, leading to a significant pre-market stock increase of 12.3% [1] Company Summary - Biohaven, a biotech company based in New Haven, Connecticut, received priority review status from the FDA for its new drug application (NDA) for trorluzole, aimed at treating spinocerebellar ataxia, a rare neurodegenerative disease [1] - The FDA extended the review period in May to assess additional materials submitted by Biohaven in response to agency requests [1] - On August 21, the FDA notified Biohaven that the advisory committee meeting was no longer necessary for the review process [1] - Biohaven is a spin-off of Biohaven Pharmaceutical, which was acquired by Pfizer in 2022, and the company expects the FDA to make a decision on its NDA by Q4 2025 [1]

Core Insights - Biohaven Ltd. reported its financial results for Q2 2025, highlighting significant progress in clinical development and upcoming regulatory decisions, particularly regarding VYGLXIA® for spinocerebellar ataxia (SCA) [1][2][3] Financial Performance - Cash, cash equivalents, marketable securities, and restricted cash totaled approximately $408.2 million as of June 30, 2025 [4][10] - R&D expenses were $184.4 million for Q2 2025, a decrease from $314.8 million in Q2 2024, primarily due to a one-time non-cash expense in the previous year [11] - General and administrative expenses increased to $27.3 million in Q2 2025 from $19.0 million in Q2 2024, attributed to higher non-cash share-based compensation and legal costs [12] - The net loss for Q2 2025 was $198.1 million, or $1.94 per share, compared to a net loss of $319.8 million, or $3.64 per share, in Q2 2024 [14][20] Clinical Development Highlights - The VYGLXIA NDA for SCA has a PDUFA date set for Q4 2025, with clinical trial inspections completed without observations [4][7] - BHV-1300, a MoDE degrader, showed IgG reductions of up to 87% in Phase 1 trials, indicating potential for treating IgG-mediated diseases [4][5] - BHV-1400, a TRAP degrader, achieved sustained reductions in Gd-IgA1 of over 80%, highlighting its potential for IgA Nephropathy treatment [4][5] - BHV-1510 demonstrated tumor reduction in all six patients treated in a Phase 1/2 study, indicating promising early clinical activity [4][9] - A pivotal Phase 2/3 study for BHV-8000 in Parkinson's disease has been initiated, targeting critical inflammatory pathways [4][7] Upcoming Milestones - Biohaven is preparing for the potential commercial launch of VYGLXIA if approved, with continued excellence in study execution and patient enrollment expected [2][7] - The company anticipates initiating a Phase 2 study in obesity in the second half of 2025 and a pivotal major depressive disorder topline result in the same timeframe [7][8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Biohaven Ltd. securities during the specified class period of the upcoming lead plaintiff deadline on September 12, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Biohaven securities between March 24, 2023, and May 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 12, 2025 deadline [2]. - The lawsuit claims that throughout the class period, Biohaven made false and misleading statements regarding the regulatory prospects of its drug troriluzole and its efficacy for treating bipolar disorder, which negatively impacted the company's business and financial condition [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Core Viewpoint - Class action lawsuits have been filed against several publicly-traded companies, alleging misleading statements and failure to disclose critical information that may have impacted shareholders' investments [1]. Group 1: Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims & Hers Health, Inc. is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include deceptive promotion and selling of illegitimate versions of Wegovy, risking patient safety, and potential termination of collaboration with Novo Nordisk [2]. Group 2: iRobot Corporation (NASDAQ: IRBT) - The class period for iRobot Corporation is from January 29, 2024, to March 11, 2025, with a lead plaintiff deadline of September 5, 2025 [3]. - Allegations state that iRobot overstated the effectiveness of its Restructuring Plan post-Amazon Acquisition, raising doubts about its ability to operate profitably as a standalone company [3]. Group 3: Centene Corporation (NYSE: CNC) - The class period for Centene Corporation is from December 12, 2024, to June 30, 2025, with a lead plaintiff deadline of September 8, 2025 [4]. - Allegations include lower-than-expected enrollment and increased market morbidity affecting over two-thirds of Centene's marketplace share, leading to misleading statements about the company's prospects [4]. Group 4: Biohaven Ltd. (NYSE: BHVN) - The class period for Biohaven Ltd. is from March 24, 2023, to May 14, 2025, with a lead plaintiff deadline of September 12, 2025 [5]. - Allegations involve overstated regulatory prospects for treatments and potential negative impacts on Biohaven's business and financial condition once the truth is revealed [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Biohaven Ltd. securities, alleging misleading statements regarding the company's drug regulatory prospects and clinical efficacy during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Biohaven Ltd. securities purchased between March 24, 2023, and May 14, 2025 [1]. - Allegations include that Biohaven overstated the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which could negatively impact the company's business and financial condition [5]. Group 2: Participation Information - Investors who purchased Biohaven securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. for alleged misleading statements regarding its drug candidates, potentially impacting investors who purchased securities during the specified period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to purchasers of Biohaven securities between March 24, 2023, and May 14, 2025 [1]. - Allegations include overstated regulatory prospects for the drug troriluzole and its efficacy for treating spinocerebellar ataxia and bipolar disorder, which may have negatively affected Biohaven's business and financial condition [5]. Group 2: Investor Information - Investors who purchased Biohaven securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years, including over $438 million in 2019 [4].

Core Insights - Bexorg, Inc. has announced a multi-program research collaboration with Biohaven Ltd. to advance next-generation therapies for central nervous system (CNS) disorders [1] - Bexorg's whole-brain discovery platform is unique in its ability to restore metabolic and molecular activity in isolated human and pig brains, enabling high-resolution insights into neurodegeneration [2][5] - The collaboration aims to provide insights into pharmacokinetics, pharmacodynamics, and mechanisms of action for Biohaven's therapeutics, potentially identifying novel biomarkers for clinical trials [3] Company Overview - Bexorg is a techbio company focused on CNS drug discovery, utilizing a proprietary platform called BrainEx to generate clinically predictive data from postmortem human brains [5][6] - Biohaven is a biopharmaceutical company developing treatments in areas such as immunology, neuroscience, and oncology, with a diverse portfolio including therapies for epilepsy, mood disorders, and cancer [4] Technological Advancements - Bexorg's whole-brain perfusion technology allows for the extraction of detailed transcriptomic, proteomic, and metabolic data, which is essential for machine learning and AI-driven drug discovery [2][6] - The platform addresses the limitations of traditional preclinical models by providing a more accurate representation of human brain structure and function, thus enhancing CNS drug development [3]

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 3, 2025 ...

As filed with the Securities and Exchange Commission on September 16, 2024. Registration No. 333-281987 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ELEVAI LABS INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 5912 85-1399981 (I.R.S. Employer Identification No. ...